Iradimed (IRMD) EV to EBIT (2014 - 2026)

Iradimed (IRMD) has reported EV to EBIT for 13 consecutive years, with 181.95 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to EBIT rose 74.56% year-over-year to 181.95 in Q2 2026; TTM through Jun 2026 was 42.2, a 42.01% increase from a year earlier, with the FY2025 full-year figure at 45.6, up 54.85% from the prior year.
• EV to EBIT was 181.95 for Q2 2026 at Iradimed, up from 162.24 in the prior quarter.
• Over five years, EV to EBIT peaked at 181.95 in Q2 2026 and troughed at 70.11 in Q4 2022.
• A 5-year average of 116.0 and a median of 109.67 in 2024 frame the typical range for EV to EBIT.
• Across the five-year window, EV to EBIT tumbled 57.84% in 2022 and jumped 74.56% in 2026, its largest moves.
• Over 5 years, EV to EBIT stood at 70.11 in 2022, then jumped by 52.37% to 106.83 in 2023, then climbed by 4.38% to 111.51 in 2024, then jumped by 50.72% to 168.07 in 2025, then rose by 8.26% to 181.95 in 2026.
• The last three EV to EBIT figures came in at 181.95 (Q2 2026), 162.24 (Q1 2026), and 168.07 (Q4 2025), per Business Quant data.